Small pancreatic lesions: Is there need for EUS-FNA preoperatively? What to do with the incidental lesions?

H. Maguchi, K. Takahashi, M. Osanai, A. Katanuma
Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan

Introduction

The advantage of endoscopic ultrasonography (EUS) is its high resolution and capability of local observation [1,2]. It is one of the most accurate diagnostic methods, particularly for the pancreatobiliary region, where various advanced imaging diagnostic methods available today, such as CT and MRI [3,4]. Since EUS is most useful for diagnosing a small lesion, its usage for early diagnosis of pancreatobiliary cancer has been anticipated.

Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) was developed to enhance the diagnostic capability of EUS by providing additional pathological findings [5 – 7].

However, it is not clearly known yet whether EUS is actually useful for the diagnosis of small pancreatic tumor, whether EUS-FNA is indispensable when a small tumor is detected. It is also necessary to understand for what size of tumor EUS-FNA can be used, and if there is no risk of complication or not. This time, I introduce the present state of diagnosing small pancreatic tumors, the application of EUS-FNA, and the discussion of the points to be solved.

Detection of small pancreatic tumors

It is well known that pancreatic cancer is hard to cure and is often fatal. Since it presents no characteristic symptoms, and there is no effective medical check-up for the disease, it is difficult to diagnose it at an early stage. Thus how to detect a small pancreatic cancer has been a long standing question. With the rapid advancement in less invasive imaging diagnostic methods such as CT and MRI, it has become fairly easy in recent years to indirectly find abnormalities such as dilatation of the pancreatic duct, presence of pancreatic cyst, or dilatation of the bile duct. Nevertheless, there is limitation in diagnosing small pancreatic tumor by those methods.

Table 1 shows a comparison of US, CT and EUS in the ability to detect pancreatic carcinomas to be resected in our institute. Detection of tumors, particularly those smaller than 2 cm (TS1), was possible by EUS in most cases, except in the case of carcinoma in situ. However, detection by US was successful in 52% of the cases and by CT in 43% [Fig. 1] [4]. EUS was also helpful for detecting two different tumors located in one area [Fig. 2]. From these results, it would be a key to detecting a small pancreatic cancer to assemble indirect findings obtained by less invasive imaging examinations, and then resort to EUS [8].

Differential diagnosis of small pancreatic lesions

A number of reports have already shown the utility of EUS in the differential diagnosis of pancreatic tumors [9 – 11]. It is suitable for the diagnosis of cystic tumors, particularly the qualitative diagnosis of solid tumors presenting cystic changes (Fig. 3). Although EUS is useful in the differential diagnosis of tumors, we cannot differentiate cancerous fibrosis from inflammatory fibrosis only by the B-mode images of ultrasound. Therefore, in some cases, additional information by other modalities is required. For instance, to evaluate the vascularity of tumors is very important to differentiate pancreatic cancer from inflammatory changes. The common type of pancreatic carcinoma is usually hypovascular, in contrast to an inflammatory pancreatic mass, which is iso-vascular. Enhanced CT/MRI and contrast-enhanced US are useful for the differential diagnosis [3,4,12]. Despite the advancement in diagnostic imaging techniques, however, differentiation between pancreatic cancer and focal pancreatitis remains difficult, especially in a case of a small lesion (Fig. 4). Therefore it is sometimes required to have a tissue diagnosis. There are two methods for obtaining tissue samples from a pancreatic mass, transpapillary biopsy and/or cytology, and EUS-FNA [13 – 15].

Table 1 Detection rate of pancreatic carcinoma by each imaging modality

<table>
<thead>
<tr>
<th>US</th>
<th>CT</th>
<th>EUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TS1</td>
<td>11/21 (52.4%)</td>
<td>9/21 (42.8%)</td>
</tr>
<tr>
<td>TS2</td>
<td>42/54 (77.8%)</td>
<td>45/54 (83.3%)</td>
</tr>
<tr>
<td>TS3</td>
<td>23/24</td>
<td>23/24</td>
</tr>
<tr>
<td>TS4</td>
<td>4/4</td>
<td>4/4</td>
</tr>
</tbody>
</table>

Correspondence: Hiroyuki Maguchi · Center for Gastroenterology · Teine-Keijinkai Hospital · 1-jo 12-chome · Maeda · Teine-ku · Sapporo 006-8555 · Japan · Phone: 81-11-681-8111 · Fax: 81-11-685-2967 · E-mail: maguchi@3t.so-net.ne.jp

**Transpapillary biopsy and/or cytology vs. EUS-FNA**

Both methods have some advantages and disadvantages (Table 2). The advantages of transpapillary biopsy and/or cytology are being free from the risk of cancer cells dissemination and suitable for obtaining tissue samples from carcinoma in situ [16]. The disadvantages arise in the difficulty to obtain tissue samples from the branch duct of the pancreas, risk of ERCP-related pancreatitis, and that the techniques are sometimes difficult and the sensitivity is less than what we expected. In contrast, the advantages of EUS-FNA are being free from the ERCP-related pancreatitis and suitable for obtaining tissue samples even if cancer has not invaded the main pancreatic duct. The disadvantages are the risk of dissemination of cancer cells after EUS-FNA and the difficulty to obtain tissue samples from the carcinoma in situ; and it is not clear yet on what size of tumor EUS-FNA can be applied to.
Table 2 Transpapillary biopsy/cytology versus EUS-FNA

<table>
<thead>
<tr>
<th>Advantage</th>
<th>EUS-FNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No risk of dissemination</td>
<td>- Free of ERCP-related pancreatitis</td>
</tr>
<tr>
<td>- Suitable for obtaining samples from MPD</td>
<td>- Possible to obtain samples even if the MPD is not invited</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disadvantage</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Limitation in obtaining samples from the branch duct</td>
<td>- Risk of dissemination</td>
</tr>
<tr>
<td>- Risk of ERCP-related pancreatitis</td>
<td>- Limitation in obtaining samples from the carcinoma in situ or small</td>
</tr>
<tr>
<td>- Technical difficulty</td>
<td>pancreatic mass</td>
</tr>
<tr>
<td>- Low accuracy</td>
<td></td>
</tr>
</tbody>
</table>

Preoperative histological diagnosis of small pancreatic cancer

There are very few reports of histologically diagnosed small pancreatic carcinoma preoperatively. Yamao et al. [17] reported the results of biopsies by ERCP and EUS-FNA in operated patients with small pancreatic cancer less than 2 cm in diameter (TS1); the cancer-positive rate was 50%/48 in the use of ERCP and 100%/2/2 in the use of EUS-FNA. We have investigated the results of transpapillary biopsy/cytology in our operated patients with TS1; the cancer-positive rate was 56%/10/18. We have not performed EUS-FNA on patients with TS1 because we are very concerned with dissemination of malignant cells after EUS-FNA.

Indication of EUS-FNA for small pancreatic mass lesions

A fundamental principle in establishing indication for EUS-FNA is the determination as to whether or not the information obtained has the potential to affect patient management [18]. According to this principle, EUS-FNA is currently indicated for pancreatic mass lesions for (1) histological evidence required for chemotherapy and/or radiation therapy, (2) differential diagnosis between localized pancreatitis and pancreatic cancer which shows an atypical imaging pattern and/or is negative for biopsy/cytology by transpapillary approach, and (3) tumor staging in a patient with a small amount of ascitis or lymph node swelling [17]. However, the role of EUS-FNA in patients suspected of having pancreatic cancer that appears to be respectable on imaging studies especially small lesion is controversial. One view is that a tissue diagnosis will not alter patient management, and is therefore unnecessary. This is because as with EUS-FNA for pancreatic masses have a low negative predictive value for malignancy. Thus, FNA negative for cancer will not exclude the suspected diagnosis of cancer and the patient will be explored anyway. In addition, the risk of tumor seeding by EUS-FNA is strongly stressed in the opinions against the indication of this approach, especially in Japan [17]. It has not fully been determined whether tumor seeding occurs with EUS-FNA. There have been three reports of seeding possibly caused by EUS-FNA [18–21]. Paquin et al. [21] reported of tumor seeding after EUS-FNA in patients with pancreatic cancer even though the tumor size was 8 mm.

Theoretically tumor seeding may occur more frequently in cystic lesions than in solid lesions [17–19], and the complication from EUS-FNA appears to have a greater risk of infections in cystic lesions; the incidence rate is 14% compared to 0.5% in solid masses. For this reason, indication or contraindication of EUS-FNA for pancreatic cystic lesions suspected of being necrotic cystic tumors is a matter of controversy in Japan, which explains why EUS-FNA has actively been performed for such lesions in the United States and Europe [22,23], but not in Japan. In view of the above, it will be our future task to further the study of tumor seeding and to devise a reliable method of tissue sampling in the use of EUS-FNA.

References


Maguchi H et al. Small pancreatic lesions... Endoscopy 2006; 38 (S1): 553–556

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.


